Core Viewpoint - The strategic importance of medical device logistics and distribution is increasingly recognized as the market for medical devices continues to expand, leading to a strong demand for specialized and efficient logistics services [1][8]. Industry Overview - Medical device logistics and distribution involves the effective transfer of medical device products from suppliers or manufacturers to medical institutions, pharmacies, or other relevant endpoints, ensuring safety, timeliness, and accuracy [2][3]. - The industry has evolved through four stages, from minimal focus during the early marketization phase to a rapid development period from 2010 to 2020, driven by increasing demand and regulatory policies [3]. Industry Policies - Recent government policies have provided strong support for the development of the medical device logistics industry, promoting standardization, efficiency, and scale [4]. - Key policies include the establishment of a risk-sharing alliance for online sales of medical devices and encouragement for wholesale companies to integrate storage and transportation resources [4]. Industry Chain - The upstream of the medical device logistics chain includes suppliers of logistics vehicles, software, medical devices, storage equipment, and packaging materials [4]. - The midstream consists of logistics service providers, which are crucial for the entire supply chain, while the downstream includes medical institutions and patients as the primary demand side [4]. Current Industry Status - The logistics total cost for medical devices in China is projected to reach 26.78 billion yuan in 2024, with a year-on-year growth of 1.88% [8]. - The logistics warehousing area is expected to be 23.58 million square meters in 2024, reflecting a 0.8% increase [8]. Market Trends - The medical device logistics industry is expected to accelerate its digital transformation and integration of intelligent technologies, utilizing IoT for real-time monitoring and big data for demand forecasting [12][14]. - Service models are evolving towards highly specialized and integrated solutions, addressing specific requirements for different categories of medical devices [14]. - The logistics network is anticipated to deepen into lower-tier cities, establishing regional distribution centers to enhance efficiency and reduce costs [15].

■ 张 敏 近日，由国家医疗保障局组织的一场汇聚多方代表的专题座谈会，核心议题直指如何助力中国药械"走 出去"。这向外界释放出清晰的产业信号：中国药械"出海"，已经从单兵突进，正式迈入由国家平台赋 能、企业多维攻坚的"体系化出海"新阶段。 从政策层面看，"体系化出海"正得到前所未有的系统性支持。 2026年1月份，首张"海外版药品价格证明"的颁发，为我国医药产业价格全球化提供有力支撑。同时， 多层次的市场对接网络正在形成。国家医疗保障局推动广西、新疆、天津、浙江宁波等地平台差异化发 展，面向东南亚、中亚、中东欧等共建"一带一路"国家拓展服务，搭建医药产业"出海"桥头堡。此外， 商务部、工业和信息化部、国家药监局等多部门从公共服务、产业合作、国际监管协同等方面发力，形 成了强大的政策合力，旨在降低企业"出海"的制度成本与信息壁垒。 从产业层面看，中国药械"出海"模式正发生转变。 面对历史性机遇，企业如何将体系优势转化为市场胜势？笔者认为，这要求企业完成思维转变，在多条 战线上同时修炼"内功"。 首先，夯实创新根基。"出海"的核心竞争力是不可替代的产品价值。企业需聚焦全球未满足的临床需 求，在ADC（抗体偶联药物 ...

Investment Rating - The report indicates a positive outlook for the medical equipment industry, with an expected year-on-year growth of 25% for the year 2025 [22]. Core Insights - The medical equipment industry is experiencing a slight decline in December data year-on-year, attributed to a high base effect from the previous year. However, there is a significant month-on-month increase of 38% due to accelerated budget spending at year-end [3]. - The report highlights that the current round of medical equipment upgrades is nearing its end, with expectations for a new round of equipment replacement in 2025, which is projected to be no less than the previous round [4]. - The report emphasizes the importance of government policies, including the issuance of long-term special bonds to support large-scale equipment upgrades and consumer replacement programs [15]. Summary by Relevant Sections Medical Imaging - December figures for medical imaging reached 9.8 billion yuan, a decrease of 11%, while the forecast for 2025 is 69.3 billion yuan, reflecting a growth of 37% [5]. Life Information and Support - In December, life information and support equipment generated 2.6 billion yuan, an increase of 8%, with a projected total of 16.7 billion yuan for 2025, marking a 28% growth [5]. Endoscopes - Soft endoscopes reported 1.1 billion yuan in December, down 9%, while hard endoscopes reached 1.2 billion yuan, down 7%. The 2025 projections for both are 7.8 billion yuan for soft endoscopes (+12%) and 7.8 billion yuan for hard endoscopes (+3%) [5]. Radiation Therapy - December figures for radiation therapy stood at 1.6 billion yuan, a slight increase of 1%, with a forecast of 9.6 billion yuan for 2025, indicating a growth of 32% [48]. Surgical Robots - Surgical robots saw a significant decline in December, with figures at 600 million yuan, down 24%, but are expected to reach 5.2 billion yuan in 2025, reflecting a robust growth of 54% [51]. Key Companies - Major companies in the sector include Mindray, which reported 1.9 billion yuan in December (+20%) and is projected to reach 11.2 billion yuan in 2025 (+35%), and United Imaging, with December figures of 2.2 billion yuan (0% change) and a forecast of 12.6 billion yuan (+37%) for 2025 [55][58].

Group 1 - The core viewpoint of the news highlights the performance of the medical innovation sector, with the China Securities Medical and Medical Device Innovation Index (931484) rising by 0.51% and notable increases in constituent stocks such as Ganli Pharmaceutical (3.05%) and Zhejiang Pharmaceutical (2.29%) [1] - The Medical Innovation ETF (516820) has seen a net inflow of funds over the past five days, with a peak single-day net inflow of 40.537 million yuan, totaling 62.4623 million yuan, averaging a daily net inflow of 12.4925 million yuan [1] - Baichuan Intelligent has launched the Baichuan-M3 Plus evidence-enhanced medical model, achieving a hallucination rate of 2.6%, the lowest globally, and introduced the "Evidence Anchoring" technology to provide citation sources for medical conclusions [1] Group 2 - Everbright Securities emphasizes that the AI+ healthcare sector should focus on several core areas: AI drug development, AI medical imaging, AI chronic disease management, and AI surgical robots, highlighting the strong willingness of pharmaceutical companies to invest in AI drug development due to its potential to significantly shorten drug development cycles [2] - The China Securities Medical and Medical Device Innovation Index selects 30 publicly listed companies with good profitability and growth potential from the pharmaceutical and healthcare sector, reflecting the overall performance of profitable and growth-oriented companies [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, accounting for 63.75% of the total index weight [2]

1月22日，A股早盘冲高回落，午后震荡走强，三大指数集体收红，创业板指涨近1%。在此背景下，创 业板50ETF（159949）上涨1.04%，报1.558元，换手率为5.20%，成交额达12.99亿元，位居同类ETF首 位。 | લ્લ્લ્લ | 名称 | 现价 | 涨跌幅 IOPV 流折率 | | | 换手率 成交金额 ▼ 5日涨跌幅 60日涨跌幅 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 159949 | 创业板50ETF | 1.558 | 1.04% 1.5578 0.01% | 5.20% | | 12.99亿 -1.52% | 1.30% | | 159682 | 91450ETF | 1.511 | 0.87% 1.5110 0.00% | 6.19% | 2660'E | -1.50% | 1.27% | | 159681 | @ 50ETF | 1.526 | 0.86% 1.5293 -0.22% | | 4.12% 8404.18万 | -1.48% | 0.99% | | 159373 | 创业板50ETF需实 1 ...

January 21, 2026 01:36 AM GMT 中国医疗健康行业 中国医院调研：2026年保持谨 慎乐观 我们第三次AlphaWise调研显示，2026年医院资本开支预计将 保持稳定至温和增长。带量采购有望在更多层级进一步推 进，而招标执行周期可能缩短。临床检验可能在2026年仍面 临持续的定价压力。 M 要点 2026年展望偏谨慎乐观：我们在2025年11月（对80 位医院管理者）的调研中发 现，59%的受访者预计2026年资本开支将同比增长，而2024年末调研中仅有43% 预计2025年会增长⸺仍显著低于2023年末调研时对2024年的85%。受访者预 计2026年资本开支将同比增长4.7%，高于2024年末调研对2025年3.0%的增幅预 期。值得注意的是，今年受访者预计2025年实际资本开支增速达到同比5.8%。除 了样本差异因素，这也说明医院管理层对实际需求的能见度有限，并且需求通常 在下半年集中释放。关键支出驱动因素包括：(1) 医院盈余（69%），(2) 患者需求 （50%），(3) 地方财政预算（44%）。在医疗服务量方面，疾病诊断相关分组 （DRG）/病种分值付费 （DIP）限制 ...

证券研究报告 | 金融工程 2026 年 01 月 21 日 如何一键布局"脑机接口"赛道 ——招商中证全指医疗器械 ETF 投资价值分析 在科技革命与生命健康产业升级的大趋势下，医疗器械作为新质生产力在生物 医药领域的重要载体，已成为国家重点布局的战略赛道。政策"反内卷"优化 竞争结构、创新审批体系加速落地叠加 AI 医疗与脑机接口等技术突破，正共同 推动行业由进口替代迈向自主创新与全球竞争的新阶段。医疗器械指数 ETF （159898）精准跟踪中证全指医疗器械指数，为投资者布局脑机接口、把握高 端制造升级带来的长期机会提供了便捷工具。 任瞳 S1090519080004 rentong@cmschina.com.cn 刘凯 S1090524120001 liukai11@cmschina.com.cn 研究助理 董晓宇 dongxiaoyu@cmschina.com.cn 敬请阅读末页的重要说明 q 脑机接口与人工智能正成为医疗器械行业的重要技术支点与发展方向。脑 机接口通过"神经解码—医疗干预—康复重建—智能交互"的技术路径， 能够实现传统医疗器械无法触达的治疗与康复效果；人工智能技术能够提 高医疗器械 ...

智通财经1月21日讯（编辑 梓隆），近期，A股市场整体表现平稳，部分个股则持续回落，截至今日（1 月21日）收盘，累计共有近230股当前收盘价低于"924"时（2024年9月24日）收盘价，占全市场标的近 4.3%。 跌破点位标的盘点，医药板块占比较高 按行业板块（申万一级）来统计，目前收盘价跌破"924"的个股中，医药生物股数量最高，其占比可达 18.7%，同时，食品饮料、煤炭、公用事业、基础化工、交通运输股数量也相对较多，其比例均在10% 以上。若从细分板块（申万三级）来看，白酒、中药、动力煤、焦煤、住宅开发板块的个股数量位居前 五，化学制剂、体外诊断、医疗耗材股数量也居前。 注：目前收盘价跌破"924"的个股行业分布情况（截至1月21日收盘） 市值规模层面，这两百余股目前平均总市值近436亿元，中位数总市值达108亿元。从市值分布上看，其 整体较为均衡，50亿元以下市值股近70只，占比近30%，而千亿以上市值股近20只，占比接近一成。其 中，万亿市值股共有1股，为通信股中国移动，其目前收盘价较2024年9月24日时收盘价累计回撤近 3.7%，同时股价近期在96元附近震荡。 注：目前收盘价跌破"924"的 ...

证券之星消息，1月21日医疗器械板块较上一交易日上涨0.54%，N爱舍伦领涨。当日上证指数报收于 4116.94，上涨0.08%。深证成指报收于14255.12，上涨0.7%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 688108 赛诺医疗 | | 6917.57万 | 10.43% | -2441.95万 | -3.68% | -4475.62万 | -6.75% | | 300003 乐普医疗 | | 4854.48万 | 7.83% | 516.81万 | 0.83% | -5371.29万 | -8.67% | | 688607 康众医疗 | | 4784.76万 | 10.90% | -1895.85万 | -4.32% | -2888.91万 | -6.58% | | 301235 华康洁净 | | 4691.14万 | 6.12% | -1334.42万 | -1.74 ...

医疗器械ETF（562600）当前管理费率为0.50%（每年），托管费率为0.1%（每年），没有股票账户的 投资者还可以通过链接基金（021250.OF，021251.OF）布局板块投资机遇。 1月21日，据上交所数据显示，截至13:40，上证指数上涨0.22%，医疗器械指数上涨0.69%，个股方面， 天智航 - U涨超 13%，三友医疗涨超7%，迪安诊断涨超 6%，赛诺医疗涨超5%，爱迪特涨超 4%，金域 医学涨超3%，华兰股份、新华医疗、海泰新光等涨超 2%。 1 月以来多家权威机构看好医疗器械板块走势，中信建投指出，第六批高值耗材集采规则优化 "反内 卷"，电生理、泌尿介入等赛道 2026 年将迎经营拐点，板块估值与业绩确定性有望修复；同时国产器械 出海空间广阔，手术机器人、AI 医疗等创新领域将成核心投资机会。机构普遍认为，随着国家医保局 价格政策落地、跨境交易平台逐步完善，叠加创新器械临床转化加速，2026 年医疗器械板块将实现业 绩复苏与估值修复，高端介入器械、手术机器人等细分领域增长确定性突出。 医疗器械ETF（562600）跟踪中证全指医疗器械指数，前十大权重股分别为迈瑞医疗、联影医疗、鱼跃 ...